

February 16, 2023

The Honorable Jodey Arrington  
1107 Longworth House Office Building  
Washington, DC 20515

The Honorable Darrel Issa  
2108 Rayburn House Office Building  
Washington, DC 20515

The Honorable August Pfluger  
1124 Longworth House Office Building  
Washington, DC 20515

The Honorable Debbie Dingell  
102 Cannon House Office Building  
Washington, DC 20515

The Honorable Lloyd Doggett  
2307 Rayburn House Office Building  
Washington, DC 20515

The Honorable Pramila Jayapal  
2346 Rayburn House Office  
Washington, DC 20515

Dear Representatives Arrington, Issa, Pfluger, Dingell, Doggett, and Jayapal,

On behalf of Vizient, Inc., I am pleased to offer our endorsement for your legislation to address patent thickets (H.R.6986). Your important, bipartisan legislation would encourage market competition by making it easier for generic and biosimilar drugs to enter the market, ultimately lowering the price of prescription drugs.

Vizient is the nation's largest healthcare performance improvement company. Vizient provides solutions and services that improve the delivery of high-value care by aligning cost, quality, and market performance for more than 60% of the nation's acute care providers, which includes 97% of the nation's academic medical centers and more than 25% of ambulatory providers. Vizient provides expertise, analytics, and advisory services, as well as a contract portfolio that represents more than \$130 billion in annual purchasing volume, to improve patient outcomes and lower costs. Headquartered in Irving, Texas, Vizient has offices throughout the United States.

Patent thickets, or multiple patents filed on a single existing product to extend the product's patent life, impede competition. The high cost of challenging multiple patents in court serves as a deterrent for generic and biosimilar drugs to enter the market. By limiting the number of patents per patent thicket a pharmaceutical company can assert in litigation to one, this legislation would protect innovation in the prescription drug market and encourage additional competition among drugmakers. The legislation would also prohibit a patent owner from asserting multiple patents from the same thicket in separate actions against the same alleged infringer to circumvent the intent of the law. Requiring manufacturers to only select and enforce their most suitable patent would help get lower-cost drugs to market faster, without stifling innovation in the process. We are proud to offer our support for this legislation and look forward to working with you to expedite its passage.

Thank you for your leadership in introducing this bill. Please do not hesitate to contact me at [shoshana.krilow@vizientinc.com](mailto:shoshana.krilow@vizientinc.com) or 202-354-2607 if you have any questions about Vizient or if there is any way we can be of assistance in advancing your important legislation.

Sincerely,



Shoshana Krilow  
Senior Vice President, Public Policy & Government Relations

February 16, 2023

The Honorable Peter Welch  
124 Russell Senate Office Building  
Building Washington, DC 20510

The Honorable Mike Braun  
404 Russell Senate Office  
Washington, DC 20510

The Honorable Amy Klobuchar  
425 Dirksen Senate Office Building  
Washington, DC 20510

Dear Senators Welch, Klobuchar, and Braun,

On behalf of Vizient, Inc., I am pleased to offer our endorsement for your legislation to address patent thickets (S.3583). Your important, bipartisan legislation would encourage market competition by making it easier for generic and biosimilar drugs to enter the market, ultimately lowering the price of prescription drugs.

Vizient is the nation's largest healthcare performance improvement company. Vizient provides solutions and services that improve the delivery of high-value care by aligning cost, quality, and market performance for more than 60% of the nation's acute care providers, which includes 97% of the nation's academic medical centers and more than 25% of ambulatory providers. Vizient provides expertise, analytics, and advisory services, as well as a contract portfolio that represents more than \$130 billion in annual purchasing volume, to improve patient outcomes and lower costs. Headquartered in Irving, Texas, Vizient has offices throughout the United States.

Patent thickets, or multiple patents filed on a single existing product to extend the product's patent life, impede competition. The high cost of challenging multiple patents in court serves as a deterrent for generic and biosimilar drugs to enter the market. By limiting the number of patents per patent thicket a pharmaceutical company can assert in litigation to one, this legislation would protect innovation in the prescription drug market and encourage additional competition among drugmakers. The legislation would also prohibit a patent owner from asserting multiple patents from the same thicket in separate actions against the same alleged infringer to circumvent the intent of the law. Requiring manufacturers to only select and enforce their most suitable patent would help get lower-cost drugs to market faster, without stifling innovation in the process. We are proud to offer our support for this legislation and look forward to working with you to expedite its passage.

Thank you for your leadership in introducing this bill. Please do not hesitate to contact me at [shoshana.krilow@vizientinc.com](mailto:shoshana.krilow@vizientinc.com) or 202-354-2607 if you have any questions about Vizient or if there is any way we can be of assistance in advancing your important legislation.

Sincerely,



Shoshana Krilow  
Senior Vice President, Public Policy & Government Relations